Swiss HIV Cohort Study

Ramsuran et al., Inhibiting natural killer cells in AIDS

Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells.   Science The highly polymorphic human leukocyte antigen (HLA) locus encodes cell surface proteins that are critical for immunity. HLA-A expression levels vary in an allele-dependent manner, diversifying allele-specific effects beyond peptide-binding preference. Ramsuran et al. examined data from 9’763 HIV-infected individuals from 21 […]

Pelchen-Matthews et al., Comorbidities in people living with HIV

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort.    AIDS Pelchen-Matthews et al. for the EuroSIDA study aimed to characterize the evolution of the prevalence of chronic kidney disease (CKD) and cardio-vascular disease (CVD) and related risk factors in the aging people living with HIV (PLWHIV) population in Europe. 9’798 […]

Ingle et al., Risk of viral failure in treated HIV-infected patients using different measures of adherence

Identifying risk of viral failure in treated HIV-infected patients using different measures of adherence: The Antiretroviral Therapy Cohort Collaboration.   Journal of Clinical Medicine Ingle et al. on behalf of the Antiretroviral Therapy Cohort Collaboration aimed to assess the utility of different adherence measures for identification of patients at risk of viral failure (VF). Eight cohorts […]

Walti et al., TAF in multimorbid HIV-infected patients with prior TDF-associated renal toxicity

Tenofovir alafenamide in multimorbid HIV-infected patients with prior tenofovir-associated renal toxicity.    Open Forum Infectious Diseases Walti et al. aimed to assess in a rea-life setting, whether a switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) due to prior TDF-induced renal toxicity is safe and efficacious in multimorbid individuals. In their case series, […]

Ryom et al., Les inhibiteurs de protéases VIH et leur influence sur les maladies cardiovasculaires

Les inhibiteurs de protéases VIH et leur influence sur les maladies cardiovasculaires.    Lancet HIV Les premiers inhibiteurs de protéases VIH ont été mis sur le marché au milieu des années nonante. En les combinant avec d’autres substances anti-VIH, les séropositifs ont pour la première fois pu être traités de manière efficace. Des études précédentes […]

Ryom et al., Inibitori della proteasi HIV e il loro influsso sulle malattie cardiovascolari

Inibitori della proteasi HIV e il loro influsso sulle malattie cardiovascolari.    Lancet HIV I primi inibitori della proteasi HIV sono arrivati sul mercato nella metà degli anni ’90. Assumendoli in combinazione con altre sostanze anti-HIV le persone sieropositive hanno per la prima volta ricevuto un trattamento efficace. Studi precedenti hanno mostrato che gli inibitori […]

Martin et al., Killer cell immunoglobulin-like receptor 3DL1 and protection against HIV-1

Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.    The Journal of Clinical Investigation HLA-B*57 control of HIV involves enhanced CD8+ T cell responses against infected cells, but extensive heterogeneity exists in the level of HIV control among B*57+ individuals. Using whole-genome sequencing of untreated B*57+ HIV-1–infected controllers and noncontrollers, Martin et […]

Ryom et al., HIV-Protease-Hemmer und deren Einfluss auf Herz-Kreislauf-Erkrankungen

HIV-Protease-Hemmer und deren Einfluss auf Herz-Kreislauf-Erkrankungen.    Lancet HIV Die ersten HIV-Protease-Hemmer kamen Mitte der Neunziger Jahre auf den Markt. In Kombination mit anderen HIV-Substanzen konnten damit HIV-positive Personen zum ersten Mal wirksam behandelt werden. Frühere Studien haben gezeigt, dass die erste Generation der Ritonavir verstärkten Protease-Hemmer mit einem erhöhten Risiko für Herzkreislauferkrankungen vergesellschaftet war. […]

Mocroft et al., Greatest impact of uncontrolled HIV infection

Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?    AIDS Mocroft et al. for the EuroSIDA Study aimed to identify whether risk of HIV disease progression comparing controlled and uncontrolled HIV was different across age groups, year of follow-up or European regions of care between 2001 and 2016. […]

Bachmann et al., Antiretroviral resistance and viral load monitoring

The importance of routine viral load monitoring: Higher levels of resistance at antiretroviral therapy failure in Uganda and Lesotho compared to Switzerland.    Journal of Antimicrobial Chemotherapy Bachmann et al. aimed to assess genotypic resistance patterns in two Sub-Saharan African cohorts (Uganda and Lesotho) compared to a sub-cohort of the Swiss HIV Cohort Study (SHCS). […]